Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer

Abstract

IMPORTANCE Several studies have explored the efficacy and toxic effects of concurrent 5-fluorouracil (5-FU)-or capecitabine-based chemoradiotherapy (CRT) with or without oxaliplatin in the neoadjuvant setting. Addition of oxaliplatin to 5-FU or capecitabine elicited similar outcomes but with significantly increased toxic effects; however, there is a need for randomized clinical trials comparing 2 CRT regimens for patients receiving CRT in the adjuvant setting. OBJECTIVE To explore the efficacy and toxic effects of oxaliplatin combined with postoperative concurrent capecitabine and radiotherapy (RT) for pathological stage II and III rectal cancer.

The impact of intensity‐modulated radiotherapy in conjunction with chemotherapy on proximal pT3N0 rectal cancer patients after total mesorectum excision

“…Given the continued evolution of perioperative RT and recent notable results using upfront surgery, 1 , 5 further research on the use of postoperative CCRT after upfront TME in larger patient cohorts and subgroup analyses based on tumor locations and risk stratification of patients with LARC is warranted.…”

“…At the same time, intensity‐modulated radiotherapy (IMRT) noticeably reduces complications and side effects. 5 Based on this evidence, upfront surgery has become a viable treatment choice for LARC patients at our hospital.…”

“…Other investigations have suggested that postoperative concurrent chemoradiation (CCRT) achieves 3–5‐year OS and DFS comparable to the standard treatment. At the same time, intensity‐modulated radiotherapy (IMRT) noticeably reduces complications and side effects 5 . Based on this evidence, upfront surgery has become a viable treatment choice for LARC patients at our hospital.…”